Target intelligence / Profile preview

Cerberus 1, DAN family BMP antagonist (CER1)

Target
CER1
Molecular classification
Cytokine, BMP antagonist, Member of the cysteine knot superfamily, Secreted protein, Signaling molecule
01

Overview

Cerberus 1, DAN family BMP antagonist (CER1), is a secreted cytokine and member of the cysteine knot superfamily that functions predominantly as a protein antagonist of bone morphogenetic protein (BMP), WNT, and Nodal signaling pathways[1][2][3]. CER1 plays a vital role during embryonic development, particularly in anterior-posterior patterning, head and heart induction, and establishment of left-right body axis. It achieves these functions by binding and inhibiting multiple growth factors, thereby shaping the development of craniofacial structures, neural tissue, and cardiovascular system. CER1 is expressed in the anterior visceral endoderm and its regulation is tightly linked to critical embryological events. Mutations or altered expression of CER1 are associated with congenital syndromes, altered bone mineral density, and possibly tumor biology, although no currently approved drugs target this molecule directly[1][2][3].

Other names
DAND4CerberusCerberus-related proteinDAN domain family member 4
02

Mechanism of action

No therapeutic agents targeting CER1; its mechanism is endogenous BMP, Nodal, and WNT pathway antagonism.

03

Biological functions

Antagonism of bone morphogenetic protein (BMP) signalingAntagonism of WNT and Nodal signalingAnterior neural inductionSomite formationHead, heart, and left-right body axis development in embryogenesisModulation of early embryonic patterningRegulation of cell fate during gastrulation
04

Disease associations

Congenital malformations (anterior patterning defects)Chromosome 9p deletion syndromeGenetic variants associated with osteoporosis and bone mineral density variationPotential role in breast cancer via WNT signaling modulationCardiomyopathy (dilated)
05

Safety considerations

Experimental manipulation in development shows that inappropriate expression can cause congenital anomalies (e.g., ectopic head formation, disrupted left-right symmetry, heart malformations)Not a clinical drug target; thus, therapeutic safety not defined
06

Biomarkers

CER1 polymorphisms as biomarkers for susceptibility to osteoporosis and bone mineral densityExpression in tumors for potential relevance in certain cancers [e.g., breast cancer, but not an established clinical biomarker]

Beyond the preview

Go deeper on Cerberus 1, DAN family BMP antagonist (CER1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cerberus 1, DAN family BMP antagonist (CER1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call